% s, l- z1 a, ^* ~8 x
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:4 w) [" Y, a+ ~; V6 M) R
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.5 n4 h4 e0 q) n8 _ http://www.ncbi.nlm.nih.gov/pubmed/22968184: ]$ p) Z G2 V